NCT03170349已完成不适用
The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study
Edwards Lifesciences33 个研究点 分布在 7 个国家目标入组 124 人开始时间: 2017年6月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 124
- 试验地点
- 33
- 主要终点
- Number of Participants With Major Adverse Events (MAE)
研究概览
简要总结
The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
详细描述
The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System. This is a multi-center, multi-national, prospective, single arm, safety, performance and clinical outcomes study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated IRB/ethics committee approved study consent form prior to study related procedures
- •Eighteen (18) years of age or older
- •New York Heart Association (NYHA) Functional Class II-IVa heart failure despite optimal medical therapy
- •Candidacy for surgical mitral valve repair or replacement determined by Heart Team evaluation
- •Clinically significant mitral regurgitation (moderate-to-severe or severe mitral regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE).
- •The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant.
- •Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is not measurable, pressure half-time measurement is acceptable.
排除标准
- •Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- •Leaflet anatomy which may preclude PASCAL device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation.
- •Mitral valve area (MVA) < 4.0 cm² as measured by planimetry (If MVA by planimetry is not measurable, PHT measurement is acceptable)
- •Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- •Physical evidence of right sided congestive heart failure and echocardiographic evidence of severe right ventricular dysfunction
- •Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
- •Patient is currently participating or has participated in another investigational drug or device clinical study where the primary study endpoint was not reached at time of enrollment
- •Patient is under guardianship
研究组 & 干预措施
Edwards PASCAL Transcatheter Mitral Valve Repair System
Experimental
干预措施: Mitral Valve Repair (Device)
结局指标
主要结局
Number of Participants With Major Adverse Events (MAE)
时间窗: 30 days
Composite of major adverse events (MAE) defined as cardiovascular mortality, stroke, myocardial infarction, new need for renal replacement therapy, severe bleeding and re-intervention for study device related complications at 30 days post-implant. MAEs during the first year of post-implant follow-up were adjudicated by a Clinical Events Committee of independent heart specialist physicians.
Device Success
时间窗: Exit from the cardiac catheterization laboratory
Device is deployed as intended and the delivery system is successfully retrieved as intended at the time of the patient's exit from the cardiac catheterization laboratory.
Number of Participants With Procedural Success
时间窗: through discharge
Device success with evidence of mitral regurgitation reduction to ≤ 2+ (mild-moderate) at discharge and without the need for a surgical or percutaneous intervention prior to hospital discharge. Mitral regurgitation was assessed by independent echocardiographic core laboratory review of transthoracic echocardiography (TTE) imaging.
Clinical Success
时间窗: 30 days
Procedural success with evidence of MR reduction to ≤ 2+ (mild-moderate) and without MAEs at 30 days. Mitral regurgitation was assessed by independent echocardiographic core laboratory review of transthoracic echocardiography (TTE) imaging.
次要结局
- Change in NT-proBNP, Baseline to 1-Year Visit(Baseline and 1 Year)
- Recurrent Heart Failure Hospitalization(30 days , 6 months, 1 year, 2 year, 3 year, 4 year)
- Change in PASP, Baseline to 4-Year Visit(Baseline and 4 Years)
- 6MWD by Study Visit(Baseline, 6 Months and 1 Year)
- Change in 6MWD, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in 6MWD, Baseline to 1-Year Visit(Baseline and 1 Year)
- Mitral Regurgitation Reduction(Baseline, 30 Days, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Reintervention Rates for Mitral Regurgitation(30 days, 6 months, 1 year, 2 year, 3 year, 4 year)
- LVEDV by Study Visit(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in LVEDV, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in LVESV, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in LVESV, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in PASP, Baseline to 6-Month Visit(Baseline and 6 Months)
- All-cause Mortality(30 days, 6 months, 1 year, 2 years, 3 years, 4 Years)
- Change in Mitral Regurgitant Volume, Baseline to 4-Year Visit(Baseline and 4 Years)
- Change in EQ5D VAS Score, Baseline to 1-Year Visit(Baseline and 1 Year)
- NT-proBNP by Study Visit(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in NT-proBNP, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in NT-proBNP, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in BNP, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change BNP, Baseline to 1-Year Visit(Baseline and 1 Year)
- KCCQ OS Score by Study Visit(Baseline, 30 Days, 6 Months and 1 Year)
- Change in Tricuspid Regurgitation From Baseline(6 Month, 1 Year, 2 Years, 3 Years, 4 Years)
- Mitral EROA by Study Visit(Baseline, 30 Days, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in NYHA Functional Classification(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Composite of Major Adverse Events (MAEs) Defined as Cardiovascular Mortality, Stroke, Myocardial Infarction, New Need for Renal Replacement Therapy, Severe Bleeding and Reintervention for Study Device Related Complications.(6 months, 1 year, 2 year, 3 year, 4 year)
- Change in LVEDV, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in LVEDV, Baseline to 1-Year Visit(Baseline and 1 Year)
- Change in LVEDV, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in LVEDV, Baseline to 4-Year Visit(Baseline and 4 Years)
- LVESV by Study Visit(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in LVESV, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in LVESV, Baseline to 1-Year Visit(Baseline and 1 Year)
- Change in LVESV, Baseline to 4-Year Visit(Baseline and 4 Years)
- PASP by Study Visit(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in PASP, Baseline to 1-Year Visit(Baseline and 1 Year)
- Change in PASP, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in PASP, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in KCCQ OS Score, Baseline to 30-Day Visit(Baseline and 30 Days)
- Change in KCCQ OS Score, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in KCCQ OS Score, Baseline to 1-Year Visit(Baseline and 1 Year)
- EQ5D VAS Score by Study Visit(Baseline, 30 Days, 6 Months and 1 Year)
- Change in EQ5D VAS Score, Baseline to 30-Day Visit(Baseline and 30 Days)
- Change in EQ5D VAS Score, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in NT-proBNP, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in NT-proBNP, Baseline to 4-Year Visit(Baseline and 4 Years)
- BNP by Study Visit(Baseline, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in BNP, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in BNP, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in BNP, Baseline to 4-Year Visit(Baseline and 4 Years)
- Change in Mitral EROA, Baseline to 30-Day Visit(Baseline and 30 Days)
- Change in Mitral EROA, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in Mitral EROA, Baseline to 1-Year Visit(Baseline and 1 Year)
- Change in Mitral EROA, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in Mitral EROA, Baseline to 3-Year Visit(Baseline and 3 Years)
- Change in Mitral EROA, Baseline to 4-Year Visit(Baseline and 4 Years)
- Mitral Regurgitant Volume by Study Visit(Baseline, 30 Days, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years)
- Change in Mitral Regurgitant Volume, Baseline to 30-Day Visit(Baseline and 30 Days)
- Change in Mitral Regurgitant Volume, Baseline to 6-Month Visit(Baseline and 6 Months)
- Change in Mitral Regurgitant Volume, Baseline to 1-Year Visit(Baseline and 1 Year)
- Change in Mitral Regurgitant Volume, Baseline to 2-Year Visit(Baseline and 2 Years)
- Change in Mitral Regurgitant Volume, Baseline to 3-Year Visit(Baseline and 3 Years)
研究者
研究点 (33)
Loading locations...
相似试验
招募中
不适用
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical TrialTricuspid RegurgitationTricuspid Valve InsufficiencyTricuspid Valve DiseaseNCT04097145Edwards Lifesciences1,270
进行中（未招募）
不适用
Exploratory Study of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW Canada)Heart FailureNCT04000607Edwards Lifesciences45
撤回
不适用
ExplorATory Study oF the EdWards Transcatheter Atrial Shunt System (AlT FloW Germany)Heart FailureNCT04965623Edwards Lifesciences15
已完成
不适用
Micra Transcatheter Pacing StudyClass I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National GuidelinesNCT02004873Medtronic Cardiac Rhythm and Heart Failure744
进行中（未招募）
不适用
Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair SystemTricuspid Valve InsufficiencyNCT04614402Edwards Lifesciences300